Evidence map›Paper›PMID 41123341›Full record

ArticlemSystems2025

A 1-year study on SARS-CoV-2 variant shifts in wastewater using dPCR: comparison with clinical and GISAID data.

Sayed Mohammad R Mosavi, Patrick Acer, Patrick Andersen, Robbie Barbero, Stephanie Barksdale, Sophia Bellakbira, Dalton Bunde, Ross Dunlap, James Erickson, Daniel Goldfarb and 53 more

Abstract readComparative Study
In one paragraph

Article in mSystems, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

63 authors.

Sayed Mohammad R MosaviCeres Nanosciences Inc., Manassas, Virginia, USA.ORCID 0009-0001-3711-6870
Patrick AcerCeres Nanosciences Inc., Manassas, Virginia, USA.
Patrick AndersenCeres Nanosciences Inc., Manassas, Virginia, USA.
Robbie BarberoCeres Nanosciences Inc., Manassas, Virginia, USA.
Stephanie BarksdaleCeres Nanosciences Inc., Manassas, Virginia, USA.
Sophia BellakbiraCeres Nanosciences Inc., Manassas, Virginia, USA.
Dalton BundeCeres Nanosciences Inc., Manassas, Virginia, USA.
Ross DunlapCeres Nanosciences Inc., Manassas, Virginia, USA.
James EricksonCeres Nanosciences Inc., Manassas, Virginia, USA.
Daniel GoldfarbCeres Nanosciences Inc., Manassas, Virginia, USA.
Tara Jones-RoeCeres Nanosciences Inc., Manassas, Virginia, USA.
Michael KilroyCeres Nanosciences Inc., Manassas, Virginia, USA.
Hien LeCeres Nanosciences Inc., Manassas, Virginia, USA.
Benjamin LepeneCeres Nanosciences Inc., Manassas, Virginia, USA.
Emily MilichCeres Nanosciences Inc., Manassas, Virginia, USA.
Ayan MohamedCeres Nanosciences Inc., Manassas, Virginia, USA.
Denton MunnsCeres Nanosciences Inc., Manassas, Virginia, USA.
Jared ObermeyerCeres Nanosciences Inc., Manassas, Virginia, USA.
Anurag PatnaikCeres Nanosciences Inc., Manassas, Virginia, USA.
Ganit PricerCeres Nanosciences Inc., Manassas, Virginia, USA.
Marion T RevenCeres Nanosciences Inc., Manassas, Virginia, USA.
Dalaun RichardsonCeres Nanosciences Inc., Manassas, Virginia, USA.
Chamodya RuhunusiriCeres Nanosciences Inc., Manassas, Virginia, USA.
Saswata K SahooCeres Nanosciences Inc., Manassas, Virginia, USA.
Lauren P SaundersCeres Nanosciences Inc., Manassas, Virginia, USA.
Olivia SwahnCeres Nanosciences Inc., Manassas, Virginia, USA.
Kalpita VengurlekarCeres Nanosciences Inc., Manassas, Virginia, USA.
David WhiteCeres Nanosciences Inc., Manassas, Virginia, USA.
Jeremy Davis-TurakRosalind, Inc., San Diego, California, USA.
Aaron StanzRosalind, Inc., San Diego, California, USA.
Aouda P Flores-BaffiRosalind, Inc., San Diego, California, USA.
Jean LozachRosalind, Inc., San Diego, California, USA.
Tim WesselmanRosalind, Inc., San Diego, California, USA.
Stephen HiltonCenter for Global Safe Water, Sanitation, and Hygiene at Emory University, Atlanta, Georgia, USA.
Siya KashwalaCenter for Global Safe Water, Sanitation, and Hygiene at Emory University, Atlanta, Georgia, USA.
Pengbo LiuCenter for Global Safe Water, Sanitation, and Hygiene at Emory University, Atlanta, Georgia, USA.
Christine L MoeCenter for Global Safe Water, Sanitation, and Hygiene at Emory University, Atlanta, Georgia, USA.
Orlando SablonCenter for Global Safe Water, Sanitation, and Hygiene at Emory University, Atlanta, Georgia, USA.
Yuke WangCenter for Global Safe Water, Sanitation, and Hygiene at Emory University, Atlanta, Georgia, USA.
Marlene WolfeCenter for Global Safe Water, Sanitation, and Hygiene at Emory University, Atlanta, Georgia, USA.
Dagmara AntkiewiczUniversity of Wisconsin Madison, Madison, Wisconsin, USA.
Erica CamaratoUniversity of Wisconsin Madison, Madison, Wisconsin, USA.
Kayley JanssenUniversity of Wisconsin Madison, Madison, Wisconsin, USA.
Adélaïde RoguetUniversity of Wisconsin Madison, Madison, Wisconsin, USA.
Shreya ShresthaUniversity of Wisconsin Madison, Madison, Wisconsin, USA.
Regan WiedUniversity of Wisconsin Madison, Madison, Wisconsin, USA.
Johannah GillespieGT Molecular, Fort Collins, Colorado, USA.
Jim HuangGT Molecular, Fort Collins, Colorado, USA.
Andrew JonesGT Molecular, Fort Collins, Colorado, USA.
Sarah KaneGT Molecular, Fort Collins, Colorado, USA.
Dolores S GonzalezUniversity of Illinois Chicago, Chicago, Illinois, USA.
Modou L JarjuUniversity of Illinois Chicago, Chicago, Illinois, USA.
Chi-Yu LinUniversity of Illinois Chicago, Chicago, Illinois, USA.
Mayumi E PascualUniversity of Illinois Chicago, Chicago, Illinois, USA.
Rachel PoretskyUniversity of Illinois Chicago, Chicago, Illinois, USA.ORCID 0000-0001-5401-449X
Michael SecretoUniversity of Illinois Chicago, Chicago, Illinois, USA.
Ian BradleyUniversity at Buffalo-SUNY, Buffalo, New York, USA.
Sydney GalloUniversity at Buffalo-SUNY, Buffalo, New York, USA.
Yinyin YeUniversity at Buffalo-SUNY, Buffalo, New York, USA.ORCID 0000-0003-0625-9657
Elizabeth DonahueArgonne National Laboratory, Lemont, Illinois, USA.
Stephanie M GreenwaldArgonne National Laboratory, Lemont, Illinois, USA.
Sarah OwensArgonne National Laboratory, Lemont, Illinois, USA.
Rosemarie WiltonArgonne National Laboratory, Lemont, Illinois, USA.

Funding

AWARD A CONTRACT FOR RADX TECH - CERES TO DEVELOP A WASTEWATER COVID-19 SURVEILLANCE FRAMEWORK DRIVEN BY PUBLIC HEALTH AUTHORITIES AT CITY, COUNTY AND75N92021C00012 · NHLBI · CERES NANOSCIENCES, LLLP · PI DUNLAP, ROSS · 2021 to 2021
$8.2M
NHLBI NIH HHS 75N92021C00012NHLBI NIH HHS 75N92023C00002
6 · The paper itself

Abstract

Wastewater testing can be used to monitor SARS-CoV-2 infections in communities. Data from PCR-based wastewater testing are usually available to public health authorities within 5-7 days after excreta and other body fluids enter the sewer. While PCR-based methods can accurately detect and quantify SARS-CoV-2, sequencing-based methods are usually required to distinguish between variants, delaying the results and adding cost to the process. We developed and assessed a novel, customizable digital PCR (dPCR)-based genotyping method for SARS-CoV-2 variant detection in wastewater, which is more cost-effective, faster, and more accessible than sequencing. This approach was applied to more than 1,400 wastewater samples collected from six states between April 2023 and May 2024, with results displayed on a public dashboard alongside clinical data from the same period. The wastewater dPCR-based method effectively detected emerging variants, mirroring trends observed in clinical settings and in data on the Global Initiative on Sharing All Influenza Data (GISAID) platform; this method also provided early warning signals, as variants like EG.5 and FL were identified in wastewater before clinical detection. A subset of the wastewater samples was analyzed using both dPCR genotyping and sequencing, with good agreement between the two methods. The range of concordance for four different variants was between 62% and 98%. The successful development and implementation of this dPCR-based genotyping for wastewater samples demonstrates its cost-effectiveness and scalability. With the decline in clinical testing, wastewater surveillance becomes increasingly vital for monitoring SARS-CoV-2 variants and supplementing clinical surveillance efforts. IMPORTANCE: As clinical specimens are collected and analyzed less for SARS-CoV-2, variant detection in wastewater provides a readily accessible and rich source of information on SARS-CoV-2 evolution. The detection of pathogen targets in wastewater samples using PCR assays is a sensitive, cost-effective way to monitor the levels of infectious diseases, like SARS-CoV-2, in a community. Unfortunately, because PCR-based methods are typically not used to distinguish between viral variants, most wastewater testing labs must rely on more expensive, time-consuming, and resource-intensive sequencing methods for these results. Building upon recent developments for variant detection using quantitative PCR, we developed and assessed a novel, customizable digital PCR-based genotyping method for SARS-CoV-2 variant detection in wastewater, which is more rapid, cost-effective, and accessible than sequencing. We characterize the method and offer insights for improvement in future implementations.

Indexed as

COVID-19Polymerase Chain ReactionSARS-CoV-2WastewaterGenotypeHumansWastewaterdigital PCR (dPCR)genotypingmutationsOmicronSARS-CoV-2variantswastewater-based epidemiology (WBE)whole-genome sequencing (WGS)

Identifiers

PMID41123341
PMCPMC12625748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.